% | $
Quotes you view appear here for quick access.

Aradigm Corporation Message Board

  • sweetliberty17761776 sweetliberty17761776 Jun 10, 2013 5:13 PM Flag

    of interest???

    AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
    The acquisition of the privately held company secures AstraZeneca a position in the emerging market for a new class of lung treatments known as LABA/LAMA drugs that promise improved patient compliance and disease control, without steroids.

    Some industry analysts believe that LABA/LAMA inhalers are set to dominate future therapy for chronic obstructive pulmonary disease (COPD), which causes debilitating breathlessness and affects an estimated 210 million people worldwide.

4.42+0.02(+0.45%)May 31 3:59 PMEDT